Model users can accept health-economic (HE) decision models as valid without further examination, thereby reducing model confidence, or they can validate models themselves, implying overlap with the validation efforts of the modelling team. Existing modelling and validation guidelines give little guidance in setting priorities for validation, nor do they address the issue of overlapping work by model developers and users. |
Assessment of the Validation Status of Health-Economic decision models (AdViSHE) allows model developers to provide model users with structured information regarding the validation status of their HE decision model. Its main purpose is to avoid some of the current overlap in validation efforts and provide information on a list of priority validation items, selected by a Delphi consensus process. AdViSHE can be used to reproduce stated results and guide complementary validation efforts, which is expected to increase model users’ understanding of, and confidence in, the model and its outcomes. |
1 Introduction
2 Methods
2.1 Initial List
2.2 Expert Input
Source | Number of experts contacted |
---|---|
Personal network of the project team | 129 |
Proposed replacements by invitees | 10 |
Involved in the ISPOR-SMDM Good Modeling Practices Task Force | 31 |
Authors of the CHEERS statement [11] | 6 |
Involved in the organizing committee of at least one of the ISPOR conferences (International, European, Asia–Pacific, and Latin America) between 2008 and 2014 | 140 |
Involved in the ISPOR regional chapters | 100 |
Identified by other experts | 19 |
Identified by biomedexperts.com as experts in “Economic Models” and/or “Markov Chains” | 35 |
2.3 Case Studies
3 Results
3.1 Building AdViSHE
Participant characteristics | Number (%) |
---|---|
Total number of individuals who answered in at least one round | 47 (100) |
Geographical region [26] | |
Western Europe | 28 (60) |
Southern Europe | 5 (11) |
Northern Europe | 4 (9) |
Eastern Europe | 3 (7) |
North America | 2 (4) |
Central America | 2 (4) |
South America | 1 (2) |
Southern Asia | 1 (2) |
Australia and New Zealand | 1 (2) |
Field of work | |
Academics | 25 (53) |
Consulting | 8 (17) |
Pharmaceutical industry | 8 (17) |
Government, decision making | 6 (13) |
Number of responses | |
Provided comments three times or more | 24 (50) |
Provided comments twice | 12 (26) |
Provided comments once | 12 (26) |